Browsing by Autor "Luis Corrales"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item type: Item ,
    CLICaP Guía CLICaP para el diagnóstico, tratamiento y seguimiento del cáncer de pulmón de células no pequeñas localmente avanzado
    (2024) Óscar Arrieta; Jairo Zuluaga; Andrés F. Cardona; Leonardo Rojas; Camila Ordóñez‐Reyes; Nicolle Wagner-Gutiérrez; Luis Corrales; Claudio Martín; Alejandro Patiño; Suraj Samtani
    Locally advanced (stage III) Non-small-cell lung cancer (LA-NSCLC) is a heterogeneous disease that represents a challenge due to its enormous clinical, diagnostic, and therapeutic complexity. LA-NSCLC affects approximately one-third of patients, and the optimal treatment approach is most frequently multi-modal, with systemic and local therapies for local and subclinical systemic disease control. The exact sequence and modality used are debated and case-specific. The first question always approached in the management of LA-NSCLC is whether it is potentially resectable. If the patient is a candidate for surgery, preoperative treatment (chemotherapy or chemoradiotherapy (CRT)) is an option, particularly in cases with optimal pulmonary function, mediastinal tumor clearance following upfront treatment, and no requirements for pneumonectomy. However, for the remaining patients or those diagnosed with unresectable stage LA-NSCLC, platinum-based concurrent chemoradiotherapy is the standard of care (in some cases, sequential CRT could be an option). This clinical practice guideline (CPG) has been prepared by experts who have extensively reviewed the literature. It includes evaluating information related to critical studies on diagnostic strategies, including the technical capacity to stratify mediastinal lymph node involvement. Additionally, it considers information on surgical interventions, chemotherapy, and radiation therapy. It also discusses the optimal treatable areas for radiotherapy and dose fractionation. The CPG also highlights the rationale for the benefits of immunotherapies and the incursion of adjuvant-targeted therapy in patients with LA-NSCLC with driver mutations.
  • Thumbnail Image
    Item type: Item ,
    Revolución de los conjugados anticuerpo-fármaco en el cáncer, ¿a donde vamos?
    (2024) Nicolle Wagner-Gutiérrez; Vladmir Cláudio Cordeiro de Lima; H. Freitas; Claudio Martín; Luis Corrales; Andrés F. Cardona; Óscar Arrieta
    La nanomedicina ha facilitado el desarrollo de moléculas bioactivas en diversos órganos humanos. El diseño a microescala ha superado barreras fisiológicas específicas, permitiendo mejorar el índice terapéutico, reducir la dosis biológica efectiva y disminuir las reacciones adversas (1). El objetivo principal de un sistema de administración farmacológica como los conjugados anticuerpo-fármaco (ADC) es prolongar, localizar y permitir una interacción farmacológica protegida con el tejido enfermo. Además, los sistemas de liberación dirigida reducen la frecuencia de dosificación, minimizan los efectos adversos y reducen las fluctuaciones en los niveles circulantes (el volumen de distribución de un ADC es de 6 a 10 litros y la vida media de eliminación terminal es de 4 a 6 días) (2). Los nanodispositivos capaces de modular reacciones adversas y mejorar la administración del medicamento activo (SMART) están compuestos de materiales blandos quiméricos o híbridos.